Fig. 2From: A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase I/II randomized, open-label, controlled trialImmunosuppression protocol for ABO-i LT in the MSC (a) and rituximab trial (b). LT liver transplantation; IVIG intravenous immunoglobulinBack to article page